Literature DB >> 1845034

Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications.

K D Kieburtz1, L G Epstein, H A Gelbard, J T Greenamyre.   

Abstract

Human immunodeficiency virus infection is frequently complicated by a syndrome of central nervous system dysfunction known as the acquired immunodeficiency syndrome dementia complex (ADC). The ADC is characterized by abnormalities in cognition, motor performance, and behavior, and it produces serious morbidity in a significant number of patients with acquired immunodeficiency syndrome. The pathogenesis of ADC is unclear, but appears to be caused by the human immunodeficiency virus itself, rather than by a secondary opportunistic process. Herein, we review the data regarding the pathogenesis of ADC and hypothesize a mechanism involving excitotoxicity and dopaminergic dysfunction. N-methyl-D-aspartate receptor antagonists may be of therapeutic benefit, as these agents may both limit glutamate-mediated neuronal dysfunction and improve dopaminergic neuronal function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845034     DOI: 10.1001/archneur.1991.00530240087028

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat.

Authors:  Katy M Webb; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

Review 3.  Neuropsychiatric manifestations of HIV infection and AIDS.

Authors:  Benoit Dubé; Tami Benton; Dean G Cruess; Dwight L Evans
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

4.  Age-Related Decrease in Tyrosine Hydroxylase Immunoreactivity in the Substantia Nigra and Region-Specific Changes in Microglia Morphology in HIV-1 Tg Rats.

Authors:  David R Goulding; Andrew Kraft; Peter R Mouton; Christopher A McPherson; Valeria Avdoshina; Italo Mocchetti; G Jean Harry
Journal:  Neurotox Res       Date:  2019-07-08       Impact factor: 3.911

5.  Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.

Authors:  Christina J Schier; William D Marks; Jason J Paris; Aaron J Barbour; Virginia D McLane; William F Maragos; A Rory McQuiston; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurosci       Date:  2017-05-04       Impact factor: 6.167

6.  Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults.

Authors:  Andrew J Levine; Janet S Sinsheimer; Robert Bilder; Paul Shapshak; Elyse J Singer
Journal:  J Clin Exp Neuropsychol       Date:  2011-11-14       Impact factor: 2.475

Review 7.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

Review 8.  Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment.

Authors:  Elyse J Singer; April D Thames
Journal:  Neurol Clin       Date:  2016-02       Impact factor: 3.806

9.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains.

Authors:  Adarsh M Kumar; J B Fernandez; Elyse J Singer; Deborah Commins; Drenna Waldrop-Valverde; Raymond L Ownby; Mahendra Kumar
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

Review 10.  HIV-related movement disorders: epidemiology, pathogenesis and management.

Authors:  Francisco Cardoso
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.